Live Analyst Rating Changes 1641 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Biren Amin
PIPR
Biren Amin
Piper Sandler
Wall Street Analyst
★☆☆☆☆
#2517
on 13Foresight · ranked by our own returns
32%
Success Rate
+0.2%
Average Return
22 of 68 calls profitable · -11.7% vs benchmark
📈 Across the calls we could measure, roughly 32% of Biren Amin's ratings turned a profit when each position was held for 1 year — averaging +0.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

142 Buy 15 Hold 0 Sell
Biren's Stock Coverage 68 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
OCUL
Ocular Therapeutix
 Jun 18, 2026 BUY Strong Buy
+160.4% avg upside
21 analysts
$31.00
228.64% Upside
 ·
CNTX
Context Therapeutics
 Jun 02, 2026 BUY Strong Buy
+873.3% avg upside
12 analysts
$7.00
1007.86% Upside
 ·
MNPR
Monopar Therapeutics Inc
 Jun 02, 2026 BUY Strong Buy
+45.9% avg upside
18 analysts
$101.00
49.74% Upside
 ·
REGN
Regeneron
 Jun 02, 2026 BUY Strong Buy
+26.9% avg upside
57 analysts
$855.00
40.20% Upside
 +0.8%
CATX
Perspective Therapeutics
 Jun 01, 2026 BUY Strong Buy
+280.4% avg upside
22 analysts
$16.00
442.31% Upside
 -20.0%
IMNM
Immunome
 Jun 01, 2026 BUY Strong Buy
+82.6% avg upside
16 analysts
$33.00
76.04% Upside
 -10.8%
AAPG
Ascentage Pharma Group International Unsponsored ADR
 Jun 01, 2026 BUY Strong Buy
+156.6% avg upside
10 analysts
$48.00
180.40% Upside
 ·
BBOT
BridgeBio Oncology Therapeutics
 Jun 01, 2026 BUY Strong Buy
+232.1% avg upside
10 analysts
$21.00
177.71% Upside
 -10.2%
CMPX
Compass Therapeutics
 Jun 01, 2026 BUY Strong Buy
+373.3% avg upside
19 analysts
$4.00
98.05% Upside
 -9.0%
ALLO
Allogene Therapeutics
 May 29, 2026 BUY Strong Buy
+662.1% avg upside
28 analysts
$10.00
399.94% Upside
 -12.4%
CBIO
Crescent Biopharma
 May 26, 2026 BUY Strong Buy
+26.9% avg upside
17 analysts
$35.00
97.94% Upside
 ·
NRIX
Nurix Therapeutics
 May 13, 2026 BUY Strong Buy
+75.6% avg upside
26 analysts
$35.00
99.40% Upside
 +8.7%
SLDB
Solid Biosciences
 May 13, 2026 BUY Strong Buy
+90.3% avg upside
23 analysts
$18.00
116.18% Upside
 -6.2%
LENZ
LENZ Therapeutics
 May 12, 2026 HOLD Buy
+284.0% avg upside
17 analysts
$12.00
95.07% Upside
 -13.7%
BBIO
BridgeBio Pharma
 May 12, 2026 BUY Strong Buy
+38.7% avg upside
34 analysts
$111.00
67.59% Upside
 +0.5%
ACRS
Aclaris Therapeutics
 May 11, 2026 BUY Strong Buy
+122.2% avg upside
15 analysts
$11.00
144.48% Upside
 -12.7%
IRD
Opus Genetics
 May 08, 2026 BUY Strong Buy
+154.5% avg upside
23 analysts
$11.00
170.35% Upside
 -21.5%
VKTX
Viking Therapeutics
 Apr 30, 2026 BUY Strong Buy
+141.1% avg upside
30 analysts
$71.00
133.69% Upside
 -4.9%
OKYO
OKYO Pharma Limited Sponsored ADR
 Apr 13, 2026 BUY Strong Buy
+403.2% avg upside
4 analysts
$7.00
340.32% Upside
 +6.5%
KLRS
Kalaris Therapeutics
 Mar 30, 2026 HOLD Buy
+170.1% avg upside
13 analysts
$7.00
48.28% Upside
 -7.5%
SRPT
Sarepta Therapeutics
 Mar 11, 2026 HOLD Buy
+244.5% avg upside
49 analysts
$16.00
8.65% Downside
 -10.4%
KYMR
Kymera Therapeutics
 Feb 26, 2026 BUY Strong Buy
+8.9% avg upside
36 analysts
$140.00
54.80% Upside
 -5.4%
TSHA
Taysha Gene Therapies
 Feb 25, 2026 BUY Strong Buy
+102.5% avg upside
21 analysts
$9.00
40.25% Upside
 +37.5%
CNTA
Centessa Pharmaceuticals
 Jan 16, 2026 BUY Buy
-14.4% avg upside
19 analysts
$38.00
5.13% Downside
 +80.3%
CRBP
Corbus Pharmaceuticals
 Oct 20, 2025 BUY Strong Buy
+337.2% avg upside
20 analysts
$51.00
517.41% Upside
 -39.7%
ZNTL
Zentalis Pharmaceuticals
 May 19, 2023 BUY Buy
+292.2% avg upside
16 analysts
$70.00
1791.86% Upside
 -54.2%
NBIX
Neurocrine
 Mar 03, 2022 HOLD Strong Buy
+8.0% avg upside
37 analysts
$94.00
40.71% Downside
 +15.5%
LEGN
Legend Biotech
 Aug 24, 2021 BUY Strong Buy
+140.3% avg upside
27 analysts
$56.00
100.45% Upside
 +28.0%
HRTX
Heron Therapeutics
 Jul 23, 2021 BUY Strong Buy
+6404.5% avg upside
21 analysts
$25.00
5887.94% Upside
 -78.8%
IMTX
Immatics
 Mar 17, 2021 BUY Strong Buy
+86.8% avg upside
15 analysts
$19.00
94.24% Upside
 -50.7%
AGEN
Agenus
 Mar 15, 2021 BUY Strong Buy
+164.7% avg upside
17 analysts
$7.00
133.33% Upside
 -21.8%
CCCC
C4 Therapeutics
 Mar 12, 2021 BUY Strong Buy
+330.3% avg upside
19 analysts
$51.00
1128.93% Upside
 -47.6%
QNCX
Quince Therapeutics
 Feb 16, 2021 HOLD Hold
+2750.2% avg upside
13 analysts
$34.00
3497.57% Upside
 -83.2%
EQ
Equillium
 Feb 10, 2021 BUY Strong Buy
+182.0% avg upside
14 analysts
$21.00
588.52% Upside
 -57.9%
BCYC
Bicycle Therapeutics
 Jan 15, 2021 BUY Strong Buy
+505.6% avg upside
20 analysts
$32.00
700.07% Upside
 +79.2%
BCAB
BioAtla
 Jan 11, 2021 BUY Strong Buy
+2518.4% avg upside
13 analysts
$51.00
1295.43% Upside
 -63.6%
IOVA
Iovance Biotherapeutics
 Dec 21, 2020 BUY Strong Buy
+225.7% avg upside
24 analysts
$60.00
1434.61% Upside
 -59.8%
FATE
Fate Therapeutics
 Dec 21, 2020 BUY Buy
+475.7% avg upside
31 analysts
$109.00
5115.40% Upside
 -32.7%
AUTL
Autolus Therapeutics
 Dec 09, 2020 HOLD Strong Buy
+605.8% avg upside
16 analysts
 — ·
KALA
KALA BIO
 Sep 14, 2020 HOLD Strong Buy
+5804.2% avg upside
9 analysts
$10.00
176.91% Upside
 -61.8%
CTMX
CytomX Therapeutics
 Aug 07, 2020 HOLD Strong Buy
+269.6% avg upside
21 analysts
$9.00
205.07% Upside
 -31.1%
ALKS
Alkermes
 Jul 29, 2020 HOLD Strong Buy
-17.6% avg upside
34 analysts
$18.00
59.91% Downside
 +35.2%
PCVX
Vaxcyte
 Jul 07, 2020 BUY Strong Buy
+96.1% avg upside
15 analysts
$41.00
20.29% Downside
 -25.4%
NERV
Minerva Neurosciences
 May 29, 2020 HOLD Buy
+67.8% avg upside
8 analysts
$2.00
55.26% Downside
 -20.5%
ARDX
Ardelyx
 Dec 03, 2019 BUY Strong Buy
+124.0% avg upside
21 analysts
$11.00
81.81% Upside
 -25.0%
ANAB
AnaptysBio
 Nov 08, 2019 HOLD Strong Buy
+26.1% avg upside
26 analysts
$12.00
79.17% Downside
 +183.8%
IBRX
ImmunityBio
 Nov 12, 2018 HOLD Strong Buy
+52.6% avg upside
12 analysts
$3.50
52.45% Downside
 -53.0%
TRVN
Trevena
 Oct 10, 2018 HOLD Buy
+128278.4% avg upside
11 analysts
$1.00
8908.92% Upside
 ·
CLDX
Celldex
 Aug 10, 2018 HOLD Strong Buy
+20.6% avg upside
28 analysts
$7.50
76.80% Downside
 -66.7%
OBSEF
ObsEva
 Jun 18, 2018 BUY Buy
+10799900.0% avg upside
8 analysts
$26.00
25999900.01% Upside
 ·
CRVS
Corvus Pharmaceuticals
 Jun 05, 2018 BUY Strong Buy
+114.5% avg upside
14 analysts
$17.00
42.83% Upside
 -68.2%
PVLA
Palvella Therapeutics
 Mar 19, 2018 BUY Strong Buy
+45.3% avg upside
27 analysts
$12.00
89.33% Downside
 ·
VRTX
Vertex Pharmaceuticals
 Jul 11, 2017 BUY Strong Buy
-2.6% avg upside
61 analysts
$155.00
65.59% Downside
 +32.4%
MDRX
Veradigm
 Jun 22, 2017 BUY Buy
+207.0% avg upside
22 analysts
$16.50
243.77% Upside
 -4.6%
CLLS
Cellectis SA
 Jun 06, 2017 BUY Strong Buy
+573.6% avg upside
16 analysts
$47.00
1477.19% Upside
 +25.1%
OTLK
Outlook Therapeutics
 May 15, 2017 HOLD Buy
+484.6% avg upside
11 analysts
$3.00
89.89% Upside
 -50.5%
NGNE
Neurogene
 Mar 10, 2017 HOLD Buy
+55.5% avg upside
23 analysts
$15.00
52.38% Downside
 -2.2%
XOMA
XOMA Royalty Corporation
 Jan 25, 2017 HOLD Buy
-46.5% avg upside
11 analysts
$5.00
88.12% Downside
 +617.9%
ARCT
Arcturus Therapeutics
 Jan 18, 2017 HOLD Buy
+290.9% avg upside
35 analysts
$8.75
16.25% Upside
 +29.0%
VSTM
Verastem
 Jan 12, 2017 HOLD Strong Buy
+260.2% avg upside
23 analysts
$1.50
63.55% Downside
 +154.2%
XENE
Xenon
 Mar 09, 2016 BUY Strong Buy
+19.0% avg upside
28 analysts
$11.00
79.13% Downside
 ·
ANTH
Anthera Pharmaceuticals
 Mar 09, 2016 BUY Buy
+472857042.9% avg upside
9 analysts
$9.00
899999900.08% Upside
 ·
CRDF
Cardiff Oncology
 Feb 22, 2016 BUY Strong Buy
+732.8% avg upside
18 analysts
$15.00
1139.59% Upside
 -55.2%
TLPH
Talphera
 Oct 30, 2015 BUY Buy
+332.4% avg upside
15 analysts
$7.00
542.23% Upside
 -25.1%
AMPE
Ampio Pharmaceuticals
 Aug 22, 2014 HOLD Buy
+9184.5% avg upside
4 analysts
$5.00
2630.73% Upside
 -38.0%
NKTR
Nektar Therapeutics
 May 15, 2014 BUY Buy
+16.5% avg upside
25 analysts
$15.00
75.30% Downside
 +0.9%
EXEL
Exelixis
 May 02, 2014 HOLD Strong Buy
-21.0% avg upside
33 analysts
$4.00
92.22% Downside
 -14.8%
GILD
Gilead Sciences
 Jan 27, 2010 BUY Strong Buy
-4.8% avg upside
66 analysts
$29.00
76.54% Downside
 -18.9%
🔒 63 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Biren Amin — Frequently Asked Questions
How accurate are Biren Amin's stock ratings?
Based on the calls 13Foresight could measure, about 32% of Biren's ratings were profitable over a one-year hold, with an average return of +0.2% per rating, or -11.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Biren ranked on 13Foresight?
Biren Amin is currently ranked #2517 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Biren cover?
Biren most recently has ratings on OCUL, CNTX, MNPR, REGN, CATX, IMNM, AAPG, BBOT, CMPX, ALLO, CBIO, NRIX and 56 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.